The chief financial officer of Teva Pharmaceutical Industries, Eyal Desheh, is stepping down and will likely be appointed chairman of Isracard, Bank Hapoalim’s credit card company, Israeli news websites reported on Tuesday.
Desheh joined Teva as CFO in 2008 and briefly served as acting CEO from October 2013 to February 2014.
Teva was left without a permanent chief executive in February after Erez Vigodman stepped down, leaving new management to restore confidence in the world’s biggest generic drugmaker after a series of missteps.
A string of costly acquisitions, along with delayed drug launches, have sent Teva shares plummeting and led to calls for management and structural changes, including a possible split into separate generic and branded medicine units.
Officials at Teva declined to comment on the reports.
“Hapoalim is now considering the selection of a new chairman for Isracard,” Israel’s biggest bank said in a statement, noting there were a number of candidates.
“The selection of a chairman will be subject to the recommendation of Bank Hapoalim’s board of directors and the decision of Isracard’s board.”
The appointment would also need approval from the Bank of Israel.
“When a decision is made, we will announce it to the public,” Hapoalim said.
By Tova Cohen
Source: Reuters
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).
